Topic
Pharmaceuticals
1,010 published works
As Prescribed
The Impact of the EU Pharma Package on the UK
By Morgan Lewis
As readers will be aware, at the end of 2025, the EU institutions agreed the text of the EU Pharma Package: the wholesale change to the pharmaceutical regime in the…
Truth on the Market
Borrowed Prices: Pharmaceuticals and the American Tab
The Centers for Medicare & Medicaid Services (CMS) has proposed two sweeping Innovation Center models—the Global Benchmark for Efficient Drug Pricing Model (GLOBE) and the Guarding U.S. Medicare Against Rising…
Duane Morris Vietnam
VIETNAM – FOREIGN PHARMACEUTICAL COMPANIES – IMPORT AND DISTRIBUTION- WHAT YOU MUST KNOW
Vietnam’s pharmaceutical market is among the fastest growing in Asia. With a population of over 100 million, rising healthcare expenditure, an expanding middle class, and an increasingly sophisticated regulatory framework,…
Drug Injury Watch
Risk of NAION With Semaglutide Medicines is 2 Times Higher Than SGLT2i Diabetes Drugs
By Tom Lamb
2026 Medical Article Links NAION to Ozempic, Wegovy, and Rybelsus, Again, With New Study (Posted by Tom Lamb at Drug Injury Watch) This drug safety issue of non-arteritic anterior ischemic optic neuropathy (NAION)…
BioSlice Blog
UK PMCPA releases new guidance on Package Deals: key takeaways for industry
By Libby Amos-Stone, Emma Elliston
The Prescription Medicines Code of Practice Authority (PMCPA) has published new guidance to provide clarity on the disclosure obligations and commercial governance expected from companies in relation to package deals…
Global Policy Watch
German Government launches new Pharma & MedTech Dialogue – Broad agenda, big hopes but unclear prospects
By Dr. Dr. Adem Koyuncu, Maximilian Aretz
Germany has kicked off a new Pharma and MedTech Dialogue that aims to develop new policies and regulatory reform proposals to re‑establish Germany as a competitive, innovation‑friendly location for life…
Health Law Diagnosis
Government Withdraws Appeal in 340B Rebate Pilot Program Litigation, Signaling Shift
By Ivy Miller, Robinson+Cole's Health Law Group
The recent litigation concerning the government’s 340B Rebate Model Pilot Program (the Rebate Program), as further described below, took an unexpected turn as the federal government recently signaled that it…
Drug & Device Law
No Harm, No Foul: Medicine Consumers Got What They Paid For
Simply charging a price higher than what plaintiffs want for an effective and non-defective medicine is not a consumer protection violation, and a recent order in the Northern District of…
Big Molecule Watch
Celltrion and Sandoz Launch Their Aflibercept Biosimilars in Europe
On November 27, 2025, Celltrion announced that Health Canada approved EYDENZELT® (aflibercept-boav), a biosimilar referencing Regeneron’s EYLEA® (aflibercept), in both vial and pre-filled syringe form, to treat all indications approved…
Big Molecule Watch
Sun Pharma Launches ILUMYA® in India
On December 1, 2025, Sun Pharmaceutical Industries Ltd. (“Sun Pharma”) announced the launch of ILUMYA® (tildrakizumab-asmn) in India. ILUMYA® is a humanized monoclonal antibody injection indicated for the treatment of adults…